Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Verrica Pharmaceuticals’ SEC filings can feel like reviewing a clinical protocol—dense tables on R&D spend, detailed trial updates on YCANTH, and pages of license obligations. Yet those details matter when you’re judging cash runway or the odds of FDA approval. That’s where Stock Titan steps in.
Our AI reads every new document the moment it hits EDGAR and delivers plain-English answers to the questions you actually ask: “What did the latest Verrica Pharmaceuticals quarterly earnings report 10-Q filing reveal about Phase 3 costs?” or “Did any directors buy shares in yesterday’s Verrica Pharmaceuticals insider trading Form 4 transactions?” From the 10-K sections that outline manufacturing risks to 8-K material events on trial data, we tag the passages that move the stock and explain why.
- AI-powered summaries translate biotech jargon into clear insights
- Real-time alerts for Verrica Pharmaceuticals Form 4 insider transactions
- Side-by-side views of each Verrica Pharmaceuticals annual report 10-K simplified
- Keyword search across proxy statement executive compensation tables
- Automatic highlights of 8-K trial milestones and financing updates
Whether you’re monitoring Verrica Pharmaceuticals executive stock transactions Form 4 before conference data, studying cash burn in the latest 10-Q, or just need Verrica Pharmaceuticals SEC filings explained simply, Stock Titan transforms hundreds of pages into actionable paragraphs. Stop scrolling, start understanding.
Verrica Pharmaceuticals Inc. (VRCA) filed an 8-K to disclose a Second Amendment to its March 2021 Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd.
- Up-front cash: Torii will pay Verrica an $8.0 million milestone tied to the ongoing global Phase 3 trial of YCANTH (VP-102) for common warts.
- Cost-sharing: The parties will continue to split trial expenses 50/50. Torii will advance the first $40.0 million of out-of-pocket costs; Verrica will subsequently reimburse Torii for half. If expenses exceed $40 million, Verrica will fund the overage (up to a stated cap) and Torii will reimburse 50% of that excess.
- Additional milestone: Torii agreed to a separate $10.0 million cash payment upon Japanese approval of YCANTH for molluscum contagiosum—paid in cash rather than as a trial-cost offset.
- Manufacturing rights: A technology-transfer program will allow Torii to manufacture the product. Until partial transfer is complete, Torii will buy commercial supply from Verrica at transfer pricing; thereafter Verrica will receive quarterly royalties in the high-single- to low-double-digit range.
- All other material terms of the original agreement remain unchanged.
The amendment improves Verrica’s near-term liquidity via non-dilutive funding, caps some development risk, and may accelerate commercial scale-up in Japan. A press release announcing the amendment (Exhibit 99.1) was issued on July 1, 2025.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
What is the core focus of Verrica Pharmaceuticals?
What is YCANTH and why is it significant?
What conditions are targeted by Verrica�s product pipeline?
How does Verrica Pharmaceuticals maintain clinical and regulatory excellence?
What role do strategic partnerships play in Verrica's business model?
What is VP-315 and what potential does it hold?
How does Verrica Pharmaceuticals differentiate itself within the dermatology market?
Are Verrica's treatments available for home use?
